Thiopurine 6TG Treatment Increases Tumor Immunogenicity and Response to Immune Checkpoint Blockade

In this MEDtalk, Loulieta Nazerai presents a study in which she and her team utilized thiopurine 6-thioguanine (6TG) to induce random mutations and elevate the number of neoepitopes displayed by tumor cells. The study’s results have opened the door for a phase I/II clinical trial to investigate whether thiopurine treatment can enhance the proportion of cancer patients who are otherwise resistant to treatment and may benefit from immune-checkpoint inhibitor therapy.